333 related articles for article (PubMed ID: 17552925)
1. Chemogenomics approaches to novel target discovery.
Gaither LA
Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
[TBL] [Abstract][Full Text] [Related]
2. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
3. Cancer cell-based genomic and small molecule screens.
Caldwell JS
Adv Cancer Res; 2007; 96():145-73. PubMed ID: 17161679
[TBL] [Abstract][Full Text] [Related]
4. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
5. Novel drug discovery and molecular biological methods, via DNA, RNA and protein changes using structure-function transitions: Transitional structural chemogenomics, transitional structural chemoproteomics and novel multi-stranded nucleic acid microarray.
Gagna CE; Lambert WC
Med Hypotheses; 2006; 67(5):1099-114. PubMed ID: 16828979
[TBL] [Abstract][Full Text] [Related]
6. Chemogenomics: drug discovery's panacea?
Jacoby E
Mol Biosyst; 2006 May; 2(5):218-20. PubMed ID: 16880939
[TBL] [Abstract][Full Text] [Related]
7. Antisense and RNA interference approaches to target validation in pain research.
Kurreck J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
[TBL] [Abstract][Full Text] [Related]
8. High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways.
Sachse C; Krausz E; Krönke A; Hannus M; Walsh A; Grabner A; Ovcharenko D; Dorris D; Trudel C; Sönnichsen B; Echeverri CJ
Methods Enzymol; 2005; 392():242-77. PubMed ID: 15644186
[TBL] [Abstract][Full Text] [Related]
9. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases.
Nidhi ; Glick M; Davies JW; Jenkins JL
J Chem Inf Model; 2006; 46(3):1124-33. PubMed ID: 16711732
[TBL] [Abstract][Full Text] [Related]
10. Chemogenomics: structuring the drug discovery process to gene families.
Harris CJ; Stevens AP
Drug Discov Today; 2006 Oct; 11(19-20):880-8. PubMed ID: 16997137
[TBL] [Abstract][Full Text] [Related]
11. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
[TBL] [Abstract][Full Text] [Related]
12. T-iDT : tool for identification of drug target in bacteria and validation by Mycobacterium tuberculosis.
Singh NK; Selvam SM; Chakravarthy P
In Silico Biol; 2006; 6(6):485-93. PubMed ID: 17518759
[TBL] [Abstract][Full Text] [Related]
13. [Advance in the research and discovery of novel drugs based on chemogenomics].
He BK; Ma ZC; Wang YG; Gao Y
Yao Xue Xue Bao; 2008 Nov; 43(11):1077-81. PubMed ID: 19239023
[TBL] [Abstract][Full Text] [Related]
14. Exploring the chemogenomic knowledge space with annotated chemical libraries.
Savchuk NP; Balakin KV; Tkachenko SE
Curr Opin Chem Biol; 2004 Aug; 8(4):412-7. PubMed ID: 15288252
[TBL] [Abstract][Full Text] [Related]
15. RNA interference screening for the discovery of oncology targets.
Quon K; Kassner PD
Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
[TBL] [Abstract][Full Text] [Related]
16. Yeast genomics and proteomics in drug discovery and target validation.
Parsons AB; Geyer R; Hughes TR; Boone C
Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
[TBL] [Abstract][Full Text] [Related]
17. Commercial potential of RNAi.
Jain KK
Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
[TBL] [Abstract][Full Text] [Related]
18. Druggable targets and targeted drugs: enhancing the development of new therapeutics.
Billingsley ML
Pharmacology; 2008; 82(4):239-44. PubMed ID: 18802381
[TBL] [Abstract][Full Text] [Related]
19. Antisense and RNAi: powerful tools in drug target discovery and validation.
Lavery KS; King TH
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
[TBL] [Abstract][Full Text] [Related]
20. Exploring the genetic basis of disease using RNA interference.
Kissler S; Van Parijs L
Expert Rev Mol Diagn; 2004 Sep; 4(5):645-51. PubMed ID: 15347258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
